RT @RichardPAConway: Ritchlin et al. Bimekizumab in bDMARD naive PsA. 52 week results. Not surprisingly, week 16 outcome
Tweet Content
Ritchlin et al. Bimekizumab in bDMARD naive PsA. 52 week results. Not surprisingly, week 16 outcomes sustained. No joint difference to ADA, skin slightly better @RheumNow #ACR22 Abstr#L02 https://t.co/RjCV8Hb3HR https://t.co/a0NQFyFZlt
Links
Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Ar…
https://acrabstracts.org/abstract/bimekizumab-treatment-in-biologic-dmard-naive…
Show on Archive Page
On
Display in Search Results
On
PDQ
Off